Xeris Biopharma Holdings, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 48.32 million compared to USD 29.73 million a year ago. Net loss was USD 12.19 million compared to USD 21.83 million a year ago. Basic loss per share from continuing operations was USD 0.09 compared to USD 0.16 a year ago.
For the nine months, revenue was USD 119.52 million compared to USD 77.1 million a year ago. Net loss was USD 48.87 million compared to USD 81.73 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 0.6 a year ago.